49B Stock Overview
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.35 |
| 52 Week High | US$17.80 |
| 52 Week Low | US$9.35 |
| Beta | 0.63 |
| 1 Month Change | -20.09% |
| 3 Month Change | -15.00% |
| 1 Year Change | -46.26% |
| 3 Year Change | -51.40% |
| 5 Year Change | 14.26% |
| Change since IPO | -15.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 49B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.2% | -4.9% | -1.5% |
| 1Y | -46.3% | -19.9% | 0.9% |
Return vs Industry: 49B underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 49B underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 49B volatility | |
|---|---|
| 49B Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 49B's share price has been volatile over the past 3 months.
Volatility Over Time: 49B's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10,600 | John Oyler | www.beigene.com |
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic.
BeiGene, Ltd. Fundamentals Summary
| 49B fundamental statistics | |
|---|---|
| Market cap | €12.94b |
| Earnings (TTM) | -€828.36m |
| Revenue (TTM) | €2.31b |
5.6x
P/S Ratio-15.6x
P/E RatioIs 49B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 49B income statement (TTM) | |
|---|---|
| Revenue | US$2.46b |
| Cost of Revenue | US$543.47m |
| Gross Profit | US$1.92b |
| Other Expenses | US$2.80b |
| Earnings | -US$881.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 11, 2024
| Earnings per share (EPS) | -8.44 |
| Gross Margin | 77.90% |
| Net Profit Margin | -35.86% |
| Debt/Equity Ratio | 25.0% |
How did 49B perform over the long term?
See historical performance and comparison